| Title: |
| |
| An international multi-centre trial of anastrozole vs placebo in postmenopausal women at increased risk of breast cancer and tamoxifen vs anastrozole in postmenopausal women with hormone sensitive DCIS. |
| |
| |
| Summary: |
| |
IBIS-II is designed to continue the work started in IBIS-I in determining whether a chemopreventive strategy towards breast cancer is beneficial.
IBIS-I was set up to investigate the use of the drug tamoxifen as a preventive agent for women with moderate to increased risk of developing breast cancer. IBIS-II (Prevention) will investigate the use of the drug anastrozole vs placebo in 6000 postmenopausal women aged between 40 and 70 years who have an increased risk of developing breast cancer, and IBIS-II (DCIS) will compare the use of tamoxifen versus anastrozole in 4000 postmenopausal women aged between 40 and 70 years with locally excised hormone sensitive Ductal Carcinoma In-Situ (DCIS).
A bone sub-protocol will also examine the effect of anastrozole on bone mineral density (BMD) and the risk of developing osteoporosis and fractures in 1000 women from the initial entrants in the IBIS-II (Prevention) trial. The ability of bisphosphonate treatment (a drug which prevents bone loss) to reduce the risk in women found to have low bone mineral density at trial entry will be explored. |
| |
| |
| Coordinating Group: |
| |
Australia and New Zealand:
- ANZ Breast Cancer Trials Group (ANZ BCTG)
International:
- Cancer Research UK (CRUK)
|